Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OTEZLA/OTEZLA XR safely and effectively. See full prescribing information for OTEZLA/OTEZLA XR. OTEZLA® (apremilast) tablets, for oral use OTEZLA XR™ (apremilast) extended-release tablets, for oral use Initial U.S. Approval: 2014
Medication labelWhy this: Advisory · dailymed-prescription
OTEZLA is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis. OTEZLA XR is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis. OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA XR is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease.
- generic_name
- apremilast
- product_names
- apremilast, Apremilast
- ndc
- 55513-137, 55513-137-60, 55513-137-95, 55513-369, 55513-369-55, 55513-485, 55513-485-95, 55513-485-96, 55513-497, 55513-497-60, 55513-508, 55513-508-55, 55513-518, 55513-518-04, 55513-497-51, 55513-996, 55513-996-96, 55513-996-95, 55513-497-23, 55513-519, 55513-519-30, 55513-516, 55513-516-41, 55513-517, 55513-517-04, 55513-523, 55513-523-04, 55513-521, 55513-521-19, 55513-522, 55513-522-14
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en